National and State Population-Level Estimated Economic Impact of Ocrelizumab on Cumulative Disabilities Avoided and Work Productivity Under Different Access Scenarios in the United States
Author(s)
Elmor D. Pineda, MS, RPh, PharmD, Katherine L. Rosettie, MPH, Fadoua El Moustaid, PhD.
Genentech, Inc., South San Francisco, CA, USA.
Genentech, Inc., South San Francisco, CA, USA.
Presentation Documents
OBJECTIVES: National and state population-level impacts of ocrelizumab treatment among newly diagnosed people with multiple sclerosis (pwMS) were estimated under different access scenarios on cumulative disability avoidance, work productivity and associated costs over time.
METHODS: An Expanded Disability Status Scale (EDSS)-based Markov model with annual cycles was used to estimate long-term changes in disability among pwMS treated with ocrelizumab and other MS disease-modifying therapies (DMTs). Incident pwMS cohorts entered the model each year. Key parameters included EDSS score distributions, 6-month confirmed disability progression hazard ratios, average wage, annual work hours, employment rate and health utility by EDSS score. National-level primary outcomes were predicted, including cumulative incremental disability events (significant disability [EDSS=4], walking aid usage [EDSS=6] and wheelchair usage [EDSS=7]), health-related expenses, market and nonmarket productivity loss and proportions employed. Modeled access scenarios vs baseline under current utilization rates included preferred first-line access to ocrelizumab (scenario 1) and nonpreferred anti-CD20 therapy coverage (scenario 2).
RESULTS: From 2024 to 2034, 110,549 estimated pwMS were newly diagnosed and received DMTs. Under scenario 1 vs baseline, ocrelizumab treatment was estimated to reduce the number of disability events by 2719 and increase employment rates by 4% by 2034. Cost savings included $143.7 million from avoided disabilities, $291.4 million from market productivity and $75.1 million from nonmarket productivity. Under scenario 2 vs baseline, predicted number of disability events increased by 4021 and employment rates decreased by 6% by 2034. In this restricted access scenario vs baseline, costs incurred included $224.2 million in health-related expenses, $457.1 million in market productivity and $117.4 million in nonmarket productivity. Similar impacts were observed at the state level.
CONCLUSIONS: Improving early access to ocrelizumab may offer significant value to pwMS and substantial socioeconomic benefits on national and local levels but relies on policy implementation that enhances access and earlier treatment.
METHODS: An Expanded Disability Status Scale (EDSS)-based Markov model with annual cycles was used to estimate long-term changes in disability among pwMS treated with ocrelizumab and other MS disease-modifying therapies (DMTs). Incident pwMS cohorts entered the model each year. Key parameters included EDSS score distributions, 6-month confirmed disability progression hazard ratios, average wage, annual work hours, employment rate and health utility by EDSS score. National-level primary outcomes were predicted, including cumulative incremental disability events (significant disability [EDSS=4], walking aid usage [EDSS=6] and wheelchair usage [EDSS=7]), health-related expenses, market and nonmarket productivity loss and proportions employed. Modeled access scenarios vs baseline under current utilization rates included preferred first-line access to ocrelizumab (scenario 1) and nonpreferred anti-CD20 therapy coverage (scenario 2).
RESULTS: From 2024 to 2034, 110,549 estimated pwMS were newly diagnosed and received DMTs. Under scenario 1 vs baseline, ocrelizumab treatment was estimated to reduce the number of disability events by 2719 and increase employment rates by 4% by 2034. Cost savings included $143.7 million from avoided disabilities, $291.4 million from market productivity and $75.1 million from nonmarket productivity. Under scenario 2 vs baseline, predicted number of disability events increased by 4021 and employment rates decreased by 6% by 2034. In this restricted access scenario vs baseline, costs incurred included $224.2 million in health-related expenses, $457.1 million in market productivity and $117.4 million in nonmarket productivity. Similar impacts were observed at the state level.
CONCLUSIONS: Improving early access to ocrelizumab may offer significant value to pwMS and substantial socioeconomic benefits on national and local levels but relies on policy implementation that enhances access and earlier treatment.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE450
Topic
Economic Evaluation
Topic Subcategory
Thresholds & Opportunity Cost
Disease
SDC: Neurological Disorders